Skip to main content

Table 3 Lymphocyte count as baseline (safety analysis set)

From: Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)

Lymphocytes†, × 109/L, n (%)

Upadacitinib 7.5 mg QD (n = 65)

Upadacitinib 15 mg QD (n = 64)

Upadacitinib 30 mg QD (n = 66)

Grade 0 (> 2.0)

5 (7.7)

9 (14.1)

7 (10.6)

Grade 1 (1.5 to < 2.0)

21 (32.3)

11 (17.2)

11 (16.7)

Grade 2 (1.0 to < 1.5)

33 (50.8)

31 (48.4)

37 (56.1)

Grade 3 (0.5 to < 1.0)

6 (9.2)

13 (20.3)

11 (16.7)

  1. Two subjects treated with placebo in period 1 discontinued treatment and thus were not included in the safety analysis set
  2. QD once daily
  3. †The toxicity grading is based on Outcome Measures in Rheumatology criteria (Rheumatology Common Toxicity Criteria v.2.0)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us